We have previously demonstrated that peptide fragments of human serum albumin can be developed into potential renal targeting drug carriers. However, the interactions of these peptide fragments with red blood cells and plasma components are not evaluated well and there is yet no report on the evaluation of the hemocompatibility of peptide fragments. In this study, three kinds of peptide fragments were prepared and identified by amino acid analysis, and the blood compatibility of the peptide fragments was investigated by measuring blood coagulation, platelet and complement activation and hemolysis activity. Results indicated that all the peptide fragments prepared were highly hemocompatible without causing any clot formation, red blood cell aggregation or immune response. In addition, data from the cytotoxicity assay using HeLa cells and Madin-Darby canine kidney cells suggested that these peptide fragments do not induce toxicity towards either cell lines at concentrations up to 5 mg/ml. Therefore, it can be concluded that peptide fragments exhibit good hemocompatibility with no unwanted effect on the viability of renal cells, preliminarily demonstrating that it is safe to use peptide fragments as renal targeting drug carriers.
NaahidiSWangYJZhangM. Evaluation of biocompatibility of the AC8 peptide and its potential use as a drug carrier. Mol Pharm2014; 11: 3409–3420.
2.
YuanZXHeXKWuXJ. Peptide fragments of human serum albumin as novel renal targeting carriers. Int J Pharmaceut2014; 460: 196–204.
3.
GengQSunXGongT. Peptide-drug conjugate linked via a disulfide bond for kidney targeted drug delivery. Bioconjugate Chem2012; 23: 1200–1210.
4.
ZhangZRZhengQHanJ. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells. Biomaterials2009; 30: 1372–1381.
5.
ZhengJWanYElhissiAZhangZR. Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles. Pharm Res Dordr2014; 31: 2220–2233.
6.
PengQWeiXQShaoXR. Nanocomplex based on biocompatible phospholipids and albumin for long-circulation applications. ACS Appl Mater Inter2014; 6: 13730–13737.
7.
ZhouDZhuXWangY. Preparation and characterization of a novel pH-sensitive coated microsphere for duodenum-specific drug delivery. Arch Pharm Res2012; 35: 839–850.
8.
RihovaB. Biocompatibility of biomaterials: hemocompatibility, immunocompatibility and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv Drug Deliver Rev1996; 21: 157–176.
9.
AllisonBCApplegateBMYoungbloodJP. Hemocompatibility of hydrophilic antimicrobial copolymers of alkylated 4-vinylpyridine. Biomacromolecules2007; 8: 2995–2999.
10.
DoyenNPesceAJLapresleC. Immunochemical cross-reactivity between cyanogen-bromide fragments of human-serum albumin. J Biol Chem1982; 257: 2770–2774.
11.
ShimYSYoonWJHaJ. Method validation of 16 types of structural amino acids using an automated amino acid analyzer. Food Sci Biotechnol2013; 22: 1567–1571.
12.
KainthanRKHesterSRLevinE. In vitro biological evaluation of high molecular weight hyperbranched polyglycerols. Biomaterials2007; 28: 4581–4590.
13.
AhmedMLaiBFKizhakkedathuJN. Hyperbranched glycopolymers for blood biocompatibility. Bioconjug Chem2012; 23: 1050–1058.
14.
Imran ul-haqMLaiBFChapanianR. Influence of architecture of high molecular weight linear and branched polyglycerols on their biocompatibility and biodistribution. Biomaterials2012; 33: 9135–9147.
15.
YuanZXWuXJMoJ. Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin. Eur J Pharm Biopharm2015; 94: 363–371.
16.
McMenamyRHDintzisHMWatsonF. Cyanogen bromide fragments of human serum albumin. J Biol Chem1971; 246: 4744–4750.
17.
CampagniniAFotiSJetschke-SchmachtelM. Characterization of cyanogen bromide fragments of reduced human serum albumin by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom JMS1998; 33: 673–676.
18.
MonzaniECurtoMGallianoM. Binding and relaxometric properties of heme complexes with cyanogen bromide fragments of human serum albumin. Biophys J2002; 83: 2248–2258.
19.
WangYXRobertsonJLSpillmanWB. Effects of the chemical structure and the surface properties of polymeric biomaterials on their biocompatibility. Pharm Res Dordr2004; 21: 1362–1373.
20.
KainthanRKGnanamaniMGanguliM. Blood compatibility of novel water soluble hyperbranched polyglycerol-based multivalent cationic polymers and their interaction with DNA. Biomaterials2006; 27: 5377–5390.
21.
MichelsonAD. Methods for the measurement of platelet function. Am J Cardiol2009; 103: 20A–26A.
22.
HagbergIALybergT. Blood platelet activation evaluated by flow cytometry: optimised methods for clinical studies. Platelets2000; 11: 137–150.
23.
GorbetMBSeftonMV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials2004; 25: 5681–5703.
24.
ZhangSXLiJASongY. In vitro degradation, hemolysis and MC3T3-E1 cell adhesion of biodegradable Mg-Zn alloy. Mat Sci Eng C Mater2009; 29: 1907–1912.
25.
JawandaMLaiBFLKizhakkedathuJN. Linear and hyperbranched phosphorylcholine based homopolymers for blood biocompatibility. Polym Chem UK2013; 4: 3140–3146.
26.
KainthanRKHesterSRLevinEDevineDVBrooksDE. In vitro biological evaluation of high molecular weight hyperbranched polyglycerols. Biomaterials2007; 28: 4581–4590.
27.
KeldenichSKoppRKirschfinkM. Application of a new dynamic flow model for investigating the biocompatibility of modified surfaces. ASAIO J2000; 46: 134–141.
28.
KealeyCPWhelanSAChunYJ. In vitro hemocompatibility of thin film nitinol in stenotic flow conditions. Biomaterials2010; 31: 8864–8871.
29.
MohanCCChennazhiKPMenonD. In vitro hemocompatibility and vascular endothelial cell functionality on titania nanostructures under static and dynamic conditions for improved coronary stenting applications. Acta Biomater2013; 9: 9568–9577.
30.
BourdeauP. International Council of Scientific Unions. Scientific Committee on Problems of the Environment. Short-term toxicity tests for non-genotoxic effects, Chichester, New York: Wiley, 1990.
31.
YangBZhangYLZhangXY. Facilely prepared inexpensive and biocompatible self-healing hydrogel: a new injectable cell therapy carrier. Polym Chem UK2012; 3: 3235–3238.
32.
RoggersRALinVSYTrewynBG. Chemically reducible lipid bilayer coated mesoporous silica nanoparticles demonstrating controlled release and hela and normal mouse liver cell biocompatibility and cellular internalization. Mol Pharm2012; 9: 2770–2777.
33.
NagaiMMeerlooTTakedaT. The adaptor protein ARH escorts megalin to and through endosomes. Mol Biol Cell2003; 14: 4984–4996.
34.
TakedaTYamazakiHFarquharMG. Identification of an apical sorting determinant in the cytoplasmic tail of megalin. Am J Physiol Cell Physiol2003; 284: C1105–C1113.
